Aspen to launch HPC injection in the United States
Durban, South Africa - Aspen announced earlier today that Aspen Global Incorporated ("AGI"), a wholly owned subsidiary of Aspen Holdings, expects to launch the finished dose form of Hydroxyprogesterone Caproate ("HPC"), indicated for the treatment of certain female cancers and hormonal imbalances, in the United States during its current financial year which ends on 30 June 2016.
This announcement follows the 1 December 2015 voluntary announcement issued to shareholders on the Stock Exchange News Service ("SENS"), in which it was stated that AGI had acquired the intellectual property and the approved Abbreviated New Drug Application in the United States in respect of the finished dose form of HPC.
Stephen Saad, Aspen Group Chief Executive said, "We are in advanced negotiations with a United States pharmaceutical company with proven capabilities in this category to distribute the HPC finished dose form. Aspen currently manufactures the active pharmaceutical ingredient ("API") for HPC and is a substantial supplier of HPC API to the United States."
"Aspen's launch of HPC injection is a realisation of Aspen's stated intent to develop commercial opportunities in the United States which are aligned to the intellectual property available within the Group," added Saad.
Shauneen Beukes Communications
Tel: +27 12 661-8467
Mobile: +27 82 389 8900
Fax: +27 88 012 661 8467